RNA INTERFERENCE ANIMATION
This animation was created for Alnylam Pharmaceuticals as they led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Their pioneering work has delivered the world’s first and only approved RNAi therapeutics and they are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
This asset is primarily used to educate healthcare professionals on the complicated MoA of RNAi therapeutics and how they act on a multitude of disease areas.
Are you interested in seeing how our award-winning medical animation can help you?
Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.
‘‘For experts, there’s limited time in which they will interact with this content, so getting a message across quickly is crucial, and this medium does it very well.’’
Product Manager, GSK
‘‘Their turnaround time sets them apart from the rest of the field. The fact they can turnaround lots of comments in a couple of days is impressive, whereas that took weeks with other agencies we worked with. They’re well above the benchmark.’’
Oncology Clinical Liaison, Bristol-Myers Squibb
‘‘It was a combination equally of quality of work but also the comfort and confidence that I knew I would be working with PhDs. They gave me the confidence that they would have the ability to understand. The other companies didn’t have those sorts of people on staff, they were just good animators. That was the area where I felt that I could trust Random42 would deliver.’’
Senior Product Manager, Spectranetics
‘‘I have been to a lot of conferences and I have seen a lot of videos both from competitors and internally – in my eyes it is night and day. The quality Random42 have is not one step ahead, it is far ahead compared to what I have seen before.’’
Product Manager, Amgen